Stock Events

Stock Events

Oncoinvent ASA. 

$97.09
67
+$0+0% Friday 21:00

Statistics

Day High
0.03
Day Low
0.03
52W High
97.09
52W Low
0.03
Volume
37,305
Avg. Volume
0
Mkt Cap
3.8B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

19FebExpected
Q2 2024
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
-0.13
-0.11
-0.08
-0.06
Expected EPS
N/A
Actual EPS
N/A

Financials

-16,943.31%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
149,750.93Revenue
-25.37MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BRRGF. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Incyte
INCY
Mkt Cap19.09B
Incyte Corporation focuses on the discovery, development, and commercialization of various therapeutics, including those in oncology, which competes with BerGenBio's cancer-focused pipeline.
AMGEN
AMGN
Mkt Cap187.56B
Amgen Inc. is a biotechnology company that develops and produces medicines in areas including oncology/hematology, competing directly with BerGenBio's cancer treatment developments.
Gilead Sciences
GILD
Mkt Cap173.41B
Gilead Sciences, Inc. is involved in the research, development, and commercialization of drugs in areas such as oncology, directly competing with BerGenBio's therapeutic areas.
Merck
MRK
Mkt Cap298.84B
Merck & Co., Inc. is a global healthcare company that produces pharmaceuticals across various areas, including cancer, making it a competitor to BerGenBio.
Bristol-Myers Squibb
BMY
Mkt Cap121.69B
Bristol-Myers Squibb Company offers biopharmaceutical products, including those for cancer treatment, competing with BerGenBio's oncology focus.
Novartis
NVS
Mkt Cap297.32B
Novartis AG engages in the research, development, manufacturing, and marketing of healthcare products, including oncology, which competes with BerGenBio's product range.
Pfizer
PFE
Mkt Cap161.09B
Pfizer Inc. is a research-based global biopharmaceutical company with a broad range of products including oncology treatments, competing with BerGenBio.
Roche
RHHBY
Mkt Cap321.08B
Roche Holding AG focuses on pharmaceuticals and diagnostics in oncology, among other areas, directly competing with BerGenBio's cancer therapies.
Astrazeneca
AZN
Mkt Cap315.47B
AstraZeneca PLC is a biopharmaceutical company focusing on the discovery, development, and commercialization of prescription medicines, including for cancer, competing with BerGenBio.
Lilly(Eli) &
LLY
Mkt Cap837.36B
Eli Lilly and Company is engaged in the discovery, development, manufacture, and sale of a range of pharmaceutical products, including those for cancer, making it a competitor to BerGenBio.

About

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of drugs to treat immune evasive, drug resistant, and metastatic cancers; and respiratory diseases. Its lead candidate is Bemcentinib, a bio-available small molecule AXL inhibitor, which is in Phase II clinical development in major cancer indications and COVID-19. Its Phase II clinical trial program focuses on treatment of non-small cell lung cancer, acute myeloid leukaemia, and myelodysplastic syndrome, as well as COVID-19. In addition, it is developing tilvestamab, an anti-AXL antibody that is in Phase Ib clinical trial. BerGenBio ASA has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.
Show more...
CEO
Mr. Oystein Soug M.Sc
Employees
13
Country
US
ISIN
NO0013711713

Listings

ST
SE
BGBIOO.ST
STU
DE
7BG.STU
OL
NO
ONCIN.OL
OTC Link
US
BRRGF

0 Comments

Share your thoughts

FAQ

What is Oncoinvent ASA. stock price today?▼
The current price of BRRGF is $97.09 USD — it has increased by +0% in the past 24 hours. Watch Oncoinvent ASA. stock price performance more closely on the chart.
What is Oncoinvent ASA. stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Oncoinvent ASA. stocks are traded under the ticker BRRGF.
What is Oncoinvent ASA. market cap?▼
Today Oncoinvent ASA. has the market capitalization of 3.8B
What is Oncoinvent ASA. revenue for the last year?▼
Oncoinvent ASA. revenue for the last year amounts to 149,750.93 USD.
What is Oncoinvent ASA. net income for the last year?▼
BRRGF net income for the last year is -25.37M USD.
How many employees does Oncoinvent ASA. have?▼
As of April 10, 2026, the company has 13 employees.
In which sector is Oncoinvent ASA. located?▼
Oncoinvent ASA. operates in the Materials sector.
When did Oncoinvent ASA. complete a stock split?▼
The last stock split for Oncoinvent ASA. was on January 20, 2026 with a ratio of 1:100.
Where is Oncoinvent ASA. headquartered?▼
Oncoinvent ASA. is headquartered in Oslo, US.